RxDoctor Payments Data

Michael Miller, MD

Interventional Cardiology · Montgomery, ALNPI 1891985263

Payments from drug & device makers

$1,363in general payments, 2019–2025

Across 37 payments — averaging $36.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$788
  • Amgen$213
  • Inari Medical, Inc.$80
  • Boehringer Ingelheim$56
  • Novo Nordisk$46
  • Boston Scientific$34
  • plus $145 from 8 others

What the payments were for

  • Food & beverage$1,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,363 in reported general payments places this provider in the 10th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$130,789
Medicare patients
585
Services billed
1,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab234$169,243
EliquisApixaban118$127,538
XareltoRivaroxaban65$78,718
EntrestoSacubitril/Valsartan49$56,014
Praluent PenAlirocumab50$23,894
Repatha SyringeEvolocumab20$15,379
BrilintaTicagrelor18$10,305
Ranolazine ErRanolazine58$9,620
Metoprolol Succinate456$7,290
Atorvastatin Calcium441$5,329
Ezetimibe184$5,152
Rosuvastatin Calcium306$4,766
ClopidogrelClopidogrel Bisulfate278$4,163
Prasugrel Hcl48$3,678
Isosorbide Mononitrate ErIsosorbide Mononitrate162$2,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20$78,71865 claims
NovartisEntresto$30$56,01449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →